Skip to content

CG Oncology CGON Total debt

Total debt at other companies

ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
$445.39M+32.2%
Cogent Biosciences, Inc. logo
Cogent Biosciences, Inc.COGT
$15.48M-9.4%
Tango Therapeutics logo
Tango TherapeuticsTNGX
$32.79M-11.3%
Pfizer logo
PfizerPFE
Johnson & Johnson logo
Johnson & JohnsonJNJ
Gilead Sciences logo
Gilead SciencesGILD

Other financials

Income statement

See full
Revenue$1.1M+1,983%
Operating income-$66.4M-57.3%
Net income-$60.2M-74.7%
EPS (diluted)-$0.71-57.8%

Balance sheet

See full
Cash & equivalents$33.7M-18.7%
Total equity$1.1B+54.9%
Total assets$1.1B+55.9%

Cash flow

See full
Operating cash flow-$56.9M-94.5%
CapEx$304.0K+1,800%
Free cash flow-$57.2M-95.4%

Valuation

See full
Market cap$5.39B+206%

Profitability

See full
Operating margin-4,239%-1,872pp
Net margin-3,682.6%-1,601pp
FCF margin-3,163.8%-1,351pp

Returns & leverage

See full
Return on equity-20.8%+7.1pp
Debt / equity0.0×
Current ratio31.3×+0.3×

Where this comes from

Calculated from CG Oncology’s reported figures.

Plus components not separately reported this period.

The official record: CG Oncology’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about CG Oncology's total debt.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is CG Oncology's total debt?
CG Oncology (CGON) reported total debt of $7.58M in Q1 2026.
How has CG Oncology's total debt changed year-over-year?
CG Oncology's total debt increased by 631.2% year-over-year, from $1.04M to $7.58M.
What is the long-term trend for CG Oncology's total debt?
Over 2 years (2023 to 2025), CG Oncology's total debt has grown at a 290.3% compound annual growth rate (CAGR), from $461K to $7.02M.
What does total debt mean?
Total debt represents the aggregate sum of all interest-bearing financial obligations, including short-term borrowings, the current portion of long-term debt, and long-term debt instruments. It also encompasses capitalized lease liabilities and other debt-like financing arrangements that require fixed repayment schedules. This metric serves as a comprehensive indicator of a company's total financial leverage and its reliance on external capital providers.